Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Atezolizumab + Capecitabine + Oxaliplatin |
| Synonyms | Atezolizumab + CAPEOX |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Atezolizumab | Tecentriq | RG7446|MPDL3280A | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 136 | Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in PD-L1 positive (IC >/= 5%) advanced or metastatic cisplatin ineligible urothelial carcinoma, in advanced or metastatic urothelial carcinoma not eligible for chemotherapy, in metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, as first-line therapy in metastatic PD-L1-high (TC>/=50% or IC>/=10%) NSCL without EGFR or ALK alterations, for adjuvant treatment in patients with PD-L1-positive (>=1% tumor cell expression) NSCLC, in combination with bevacizumab, paclitaxel, and carboplatin as first-line therapy for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound and carboplatin in metastatic non-squamous NSCLC with no EGFR or ALK aberrations, in combination with carboplatin and etoposide in extensive-stage small cell lung cancer (ES-SCLC), in combination with bevacizumab in hepatocellular carcinoma without prior systemic therapy, in combination with Cotellic (cobimetinib) and Zelboraf (vemurafenib) in unresectable or metastatic BRAF V600-mutated melanoma, in combination with lurbinectedin for ES-SCLC, and in pediatric and adult patients with unresectable or metastatic alveolar soft part sarcoma (FDA.gov). |
| Capecitabine | Xeloda | R340|Ro 09-1978/000 | Chemotherapy - Antimetabolite 14 | Xeloda (capecitabine) is a prodrug that is converted to 5-FU, ultimately inhibiting RNA and DNA synthesis and cell division (PMID: 28520372). Xeloda (capecitabine) is FDA-approved for use in patients with colorectal, breast, gastric, esophageal, gastroesophageal junction, and pancreatic cancer (FDA.gov). |
| Oxaliplatin | Eloxatin | Diaminocyclohexane Oxalatoplatinum | Chemotherapy - Platinum 7 | Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PMS2 negative | small intestine adenocarcinoma | sensitive | Atezolizumab + Capecitabine + Oxaliplatin | Guideline | Actionable | Tecentriq (atezolizumab) in combination with Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as adjuvant therapy (category 2A) for patients with small bowel adenocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of PMS2, MLH1, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH2 negative | colon cancer | sensitive | Atezolizumab + Capecitabine + Oxaliplatin | Guideline | Actionable | Tecentriq (atezolizumab) in combination with Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as adjuvant therapy for patients with colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | colon cancer | sensitive | Atezolizumab + Capecitabine + Oxaliplatin | Guideline | Actionable | Tecentriq (atezolizumab) in combination with Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as adjuvant therapy for patients with colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | small intestine adenocarcinoma | sensitive | Atezolizumab + Capecitabine + Oxaliplatin | Guideline | Actionable | Tecentriq (atezolizumab) in combination with Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as adjuvant therapy (category 2A) for patients with small bowel adenocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MSH6, MSH2, MLH1, or PMS2 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | small intestine adenocarcinoma | sensitive | Atezolizumab + Capecitabine + Oxaliplatin | Guideline | Actionable | Tecentriq (atezolizumab) in combination with Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as adjuvant therapy (category 2A) for patients with small bowel adenocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, MSH2, MSH6, or PMS2 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | colon cancer | sensitive | Atezolizumab + Capecitabine + Oxaliplatin | Guideline | Actionable | Tecentriq (atezolizumab) in combination with Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as adjuvant therapy for patients with colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| PMS2 negative | colon cancer | sensitive | Atezolizumab + Capecitabine + Oxaliplatin | Guideline | Actionable | Tecentriq (atezolizumab) in combination with Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as adjuvant therapy for patients with colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH2 negative | small intestine adenocarcinoma | sensitive | Atezolizumab + Capecitabine + Oxaliplatin | Guideline | Actionable | Tecentriq (atezolizumab) in combination with Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as adjuvant therapy (category 2A) for patients with small bowel adenocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MSH2, MSH6, MLH1, or PMS2 expression by IHC) (NCCN.org). | detail... |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05836584 | Phase II | Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab Atezolizumab + Capecitabine + Oxaliplatin | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer | Active, not recruiting | USA | 0 |
| NCT05870800 | Phase II | Atezolizumab + Capecitabine + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin Capecitabine + Oxaliplatin | Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER (NICER) | Recruiting | USA | 0 |
CKB BOOST